E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Lupus Nephritis |
Nefritis lúpica |
|
E.1.1.1 | Medical condition in easily understood language |
Lupus Nephritis is an inflammation of kidneys caused by systemic lupus erythematosus, an autoimmune disease (body's immune system targets its own body tissues) that can affect any part of the body. |
Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025140 |
E.1.2 | Term | Lupus nephritis |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective is to assess the long-term efficacy of secukinumab with respect to CRR over time up to Week 260 in adults with Lupus Nephritis (ISN/RPS class III or IV, with or without co-existing class V features) participant on background SoC therapy. |
El objetivo es evaluar la eficacia de secukinumab a largo plazo respecto a la respuesta renal completa (RRC) hasta la semana 260 en participantes adultos con nefritis lúpica (de clase III o IV, con o sin características coexistentes de la clase V, según la ISN/RPS) que reciban el tratamiento SoC de base. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
No aplicable |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants eligible for inclusion in this study must meet all of the following criteria: 1. Participant must have both participated in core study and completed the entire treatment period up to and including Week 104 of the core study CAIN457Q12301. 2. Participant must be deemed by the investigator to benefit from secukinumab therapy. 3. Signed informed consent must be obtained prior to participation in the study. |
Participantes elegibles para la inclusión en este estudio tienen que reunir todos los criterios siguientes: 1.El participante debe haber participado en el estudio principal CAIN457Q12301 y debe haber completado el periodo de tratamiento hasta la semana 104 incluida. 2.El investigador debe considerar que el participante se beneficiará del tratamiento con secukinumab. 3.Se deberá obtener el consentimiento informado firmado antes de la participación en el estudio. |
|
E.4 | Principal exclusion criteria |
Participants meeting any of the following criteria are not eligible for inclusion in this study. 1. Any participant taking other concomitant biologic immunomodulating agent(s) except secukinumab. 2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 3. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 Weeks). Highly effective methods are recommended due to the known teratogenic effect of SoC (MPA). Other protocol-defined exclusion criteria may apply. |
Participantes que reúnan alguno de los siguientes criterios no serán elegibles para la inclusión en este estudio. 1.Cualquier participante que tome otros fármacos inmunomoduladores biológicos concomitantes excepto secukinumab. 2.Mujeres embarazadas o en periodo de lactancia, donde embarazo se define como el estado de una mujer después de la concepción y hasta que finalice la gestación, confirmado por un resultado positivo en la analítica de gonadotropina coriónica humana (HCG). 3. Mujeres en edad fértil, definidas como toda mujer fisiológicamente capaz de quedarse embarazada, salvo que esté utilizando métodos anticonceptivos altamente eficaces durante todo el estudio o durante más tiempo si así lo indica el prospecto local aprobado (p. ej., 20 semanas en la Unión Europea [UE]). Se recomienda utilizar métodos anticonceptivos altamente eficaces debido al efecto teratogénico conocido del SoC (ácido micofenólico [AMF]).
Aplican otros criterios de exclusión definidos en el protocolo. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of participants achieving Complete Renal Response (CRR) |
Porcentaje de participantes que logren la Respuesta Renal Completa (RRC) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Over time up to Week 260 |
A lo largo del tiempo hasta la Semana 260 |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tolerabilidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Chile |
China |
Colombia |
Guatemala |
India |
Japan |
Korea, Republic of |
Mauritius |
Mexico |
Peru |
Philippines |
Russian Federation |
South Africa |
Taiwan |
Thailand |
Turkey |
United States |
Viet Nam |
Croatia |
Czechia |
Denmark |
France |
Germany |
Greece |
Italy |
Latvia |
Norway |
Portugal |
Slovakia |
Sweden |
United Kingdom |
Romania |
Spain |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente (LVLP) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 26 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 28 |